What dose of Lantus (insulin glargine) should be given to a patient on an insulin drip at 4 units per hour?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Transitioning from Insulin Drip to Lantus

For a patient on an insulin drip at 4 units/hour, start Lantus at 48 units once daily (50% of the 24-hour IV insulin requirement of 96 units), administered subcutaneously 2-4 hours before discontinuing the IV insulin. 1

Calculation Method

The total subcutaneous insulin dose equals half of the IV insulin infused over 24 hours. 1

  • Current IV insulin rate: 4 units/hour
  • Total IV insulin over 24 hours: 4 units/hour × 24 hours = 96 units
  • Total subcutaneous dose = 96 units ÷ 2 = 48 units 1
  • Lantus (basal) dose = 50% of total subcutaneous dose = 24 units 1
  • Remaining 50% (24 units) should be divided as prandial insulin before meals (8 units per meal if eating three meals) 1

Critical Timing Considerations

Administer the first Lantus dose 2-4 hours before discontinuing the insulin drip to ensure adequate overlap and prevent rebound hyperglycemia. 1 This overlap period is essential because Lantus requires time to reach therapeutic levels after subcutaneous administration, unlike IV insulin which has immediate offset once discontinued.

Adjusting for Patient Risk Factors

For high-risk patients (elderly >65 years, renal failure, or poor oral intake), reduce the calculated dose by 20-50% to prevent hypoglycemia. 1 In these populations, use lower starting doses of 0.1-0.25 units/kg/day. 1

For patients on high-dose home insulin (≥0.6 units/kg/day), reduce the total daily dose by 20% upon hospitalization. 1

Monitoring Requirements During Transition

Check point-of-care glucose before each meal and at bedtime for patients eating regular meals, targeting 140-180 mg/dL for non-critically ill hospitalized patients. 1 For patients with poor oral intake, check glucose every 4-6 hours. 1

Titrate basal insulin every 3 days based on fasting glucose patterns, with a target fasting glucose of 80-130 mg/dL. 1 Increase by 2 units if fasting glucose is 140-179 mg/dL, or by 4 units if fasting glucose is ≥180 mg/dL. 1

Prandial Insulin Component

The remaining 50% of the total subcutaneous dose (24 units in this case) must be given as prandial insulin divided among three meals, not as Lantus alone. 1 Scheduled basal-bolus regimens are superior to sliding scale monotherapy and prevent dangerous glucose fluctuations. 1

Use rapid-acting insulin (aspart, lispro, or glulisine) 0-15 minutes before meals for the prandial component. 1 Never give rapid-acting insulin at bedtime, as this significantly increases nocturnal hypoglycemia risk. 1

Common Pitfalls to Avoid

Never use sliding scale insulin as monotherapy after discontinuing the drip—this approach is explicitly condemned by all major diabetes guidelines and leads to dangerous glucose fluctuations. 1 The 75% of hospitalized patients who experienced hypoglycemia had no basal insulin dose adjustment before the next administration, demonstrating the danger of inadequate monitoring. 1

Never discontinue the insulin drip before the Lantus has time to reach therapeutic levels. 1 The lack of overlap creates a dangerous gap in insulin coverage that can precipitate severe hyperglycemia or diabetic ketoacidosis in insulin-dependent patients.

If the patient has decreased oral intake after transition, immediately reduce total daily insulin to 0.1-0.15 units/kg/day given primarily as basal insulin. 1 Continue basal insulin coverage even with minimal intake rather than relying solely on correction doses. 1

References

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the maximum dose of Lantus (insulin glargine)?
What is the recommended initial dose of Lantus (insulin glargine) for a patient with a body weight of 155 kilograms?
What adjustments should be made to the treatment plan for a patient with uncontrolled hyperglycemia on Lantus (insulin glargine) 12 units?
Is it better to administer 54 units of Lantus (insulin glargine) once daily or twice daily?
What is the appropriate starting dose of Lantus (insulin glargine) and carbohydrate ratio for a patient with a body mass index (BMI) of 38, significant weight gain, and elevated hemoglobin A1C (HbA1C) of 13.4%?
What is the recommended dosing and management strategy for allopurinol (xanthine oxidase inhibitor) in a patient with a history of gout attacks for gout prevention?
What is the diagnosis and management for a patient with low Thyroid-Stimulating Hormone (TSH), normal Free Thyroxine (FT4), low thyroxine, and high Triiodothyronine (T3) uptake?
What is the best course of action for a patient with insulin resistance, indicated by a fasting insulin level of 11.4, a Hemoglobin A1c (HbA1c) of 4.9, normal thyroid function, a history of Irritable Bowel Syndrome with Mixed features (IBS-M) and depression, and monthly weight gain?
What IV antibiotic can be given to a patient with COPD (Chronic Obstructive Pulmonary Disease) exacerbation and an allergy to azithromycin?
What is the estimated daily dose of Lantus (insulin glargine) for a patient with significant hyperglycemia requiring 4 units of insulin per hour while on dextrose (intravenous glucose solution) fluids at 100ml/hr?
Can an adult or adolescent patient with anxiety, substance dependence, and Attention Deficit Hyperactivity Disorder (ADHD) take Librium (chlordiazepoxide), naltrexone, and Strattera (atomoxetine) together?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.